Soligenix Inc. (SNGX) 1.5000 $SNGX
Soligenix Announces First Quarter 2015 Highlights and Financial Results
PR Newswire - Thu May 14, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today recent highlights and financial results for the first quarter ended March 31, 2015.
XON: 41.17 (+1.09)
Soligenix inks development deal with Emergent BioSolutions for ricin vaccine
Seeking Alpha - at Seeking Alpha - Wed May 13, 9:54AM CDT
EBS: 30.91 (+0.19)
Vista Partners Publishes May 2015 Macroeconomic & Investment Newsletter
Marketwired - Wed May 13, 8:01AM CDT
Vista Partners ("Vista"
has published its FREE Macroeconomic & Investment Monthly Newsletter for the month of May. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.
VUZI: 5.80 (+0.22), QQQ: 110.06 (+0.48)
Soligenix Announces Development Agreement with Emergent BioSolutions
PR Newswire - Wed May 13, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax(TM) drug substance protein antigen. RiVax(TM) is a vaccine candidate being developed to protect against ricin exposure. Soligenix will transfer the manufacturing processes and analytics to Emergent to conduct process development work that could potentially lead to a future commercial manufacturing collaboration.
EBS: 30.91 (+0.19), XON: 41.17 (+1.09)
Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO
PR Newswire - Mon May 04, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it will be presenting preclinical data from three of its biodefense programs at the upcoming Chemical and Biological Defense Science and Technology Conference on May 12-14, 2015 to be held at the America's Center Convention Complex at 701 Convention Plaza, St. Louis MO 63101.
XON: 41.17 (+1.09)
Soligenix Announces FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX203 in Pediatric Crohn's Disease
PR Newswire - Tue Apr 14, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that agreement has been reached with the US Food and Drug Administration (FDA) on the design of a pivotal, Phase 3 clinical trial evaluating its product, SGX203 (oral beclomethasone 17,21-dipropionate or BDP), in the treatment of pediatric Crohn's disease. SGX203 has previously been granted both orphan drug and fast track designations from the FDA for the treatment of Crohn's Disease in the pediatric population.
XON: 41.17 (+1.09)
Soligenix Inc.'s CEO Christopher Schaber Interviewed by The Life Sciences Report
Marketwired - Thu Apr 09, 8:15AM CDT
Orphan diseases associated with inflammation present excellent development opportunities for small biopharmaceutical companies and their investors. Additionally, inflammatory conditions can result from treatment with cancer therapeutics. The crossover between inflammation and oncology, coupled with vaccine programs of high strategic value, have allowed Soligenix Inc. (OTCQB: SNGX) to build a significant pipeline with substantial revenue potential. In this interview with The Life Sciences Report, Dr. Christopher J. Schaber, company President and CEO, outlines development programs targeting pediatric Crohn's disease, GI acute radiation syndrome, a rare lymphoma and the threat of ricin.
Vista Partners Publishes April 2015 Macroeconomic & Investment Newsletter
Marketwired - Wed Apr 08, 7:01AM CDT
Vista Partners ("Vista" has published its FREE Macroeconomic & Investment Monthly Newsletter for the month of April. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.
VUZI: 5.80 (+0.22), SYRX: 1.93 (+0.05)
Soligenix Announces Recent Accomplishments and Year-End 2014 Financial Results
PR Newswire - Tue Mar 24, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today recent accomplishments and financial results for the year ended December 31, 2014.
XON: 41.17 (+1.09)
Soligenix Announces Publication of Successful Preclinical Efficacy and Immunogenicity Results for Ricin Toxin Vaccine
PR Newswire - Wed Mar 11, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the publication of data demonstrating complete protection and immunogenicity of its ricin vaccine, RiVax(TM), in preclinical studies, with analyses of previous human clinical samples. RiVax(TM) employs a derivative of recombinant ricin toxin A chain. The use of the Company's proprietary vaccine stabilization technology, ThermoVax(TM) has been previously demonstrated to enhance thermostability of RiVax(TM), enabling distribution without cold chain requirements. In this work, vaccination with RiVax(TM) provided 100% protection for non-human primates (NHPs) subsequently exposed to lethal doses of aerosolized ricin. Evaluation of antibodies produced by the NHPs after vaccination identified specific neutralizing antibodies which were also expressed by humans previously vaccinated with RiVax(TM). The results were published online in the Proceedings of the National Academy of Sciences and are available at the following link: http://www.pnas.org/content/early/2015/03/05/...f32229914c .
XON: 41.17 (+1.09)
Soligenix Announces Positive Recommendation by Data Review Committee on its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
PR Newswire - Tue Mar 03, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has received a positive recommendation from the Data Review Committee (DRC) to continue enrolling into the company's Phase 2 study evaluating SGX942, a first-in-class innate defense regulator (IDR), as a treatment for oral mucositis in patients undergoing chemoradiation (CRT) therapy for head and neck cancer. Following DRC review of available data on the subjects enrolled in the trial, the committee recommended that enrollment include an additional 20 subjects randomized into either a single SGX942 dose group or the placebo group to allow for a more targeted assessment of the drug's potential effect and to inform final dose selection in this patient population.
XON: 41.17 (+1.09)
Soligenix's SGX943 And SGX101 May Be A Solution For Melioidosis Treatment
Grant Zeng, CFA - Seeking Alpha - Wed Feb 18, 1:08PM CST
A recent news release from the US Centers for Disease Control and Prevention (CDC) on inquiry into melioidosis illness at Tulane National Research Center (TNPRC) has raised the visibility and awareness of melioidosis among healthcare...
XON: 41.17 (+1.09)
Ricin Toxin Vaccine Poster Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PR Newswire - Fri Feb 13, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it presented data from its recent preclinical study that demonstrated the efficacy and safety of its heat-stabilized ricin toxin vaccine (RiVax(TM)) in a non-human primate (NHP) lethal aerosolized ricin exposure model. The data was presented in a poster session at the American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research meeting on Wednesday, February 11, 2015 at Washington Marriott Wardman Park, 2660 Woodley Rd. NW in Washington, DC.
XON: 41.17 (+1.09)
Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PR Newswire - Wed Feb 11, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it presented data from its recent preclinical study that demonstrated statistically significant efficacy of SGX943 in a mouse model of acute, lethal pneumonic melioidosis. The data was presented in an oral presentation at the American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research meeting on Tuesday, February 10, 2015 at Washington Marriott Wardman Park, 2660 Woodley Rd. NW in Washington, DC.
XON: 41.17 (+1.09)
Soligenix to Present at the 17th Annual BIO CEO & Investor Conference in New York City
PR Newswire - Thu Feb 05, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 17th Annual BIO CEO Investor Conference in New York City, on Tuesday, February 10, 2015 at 1:30 PM Eastern Standard Time (EST). The presentation will take place in the Conrad room at the Waldorf Astoria.
XON: 41.17 (+1.09)
Soligenix Announces Presentation and Poster at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PR Newswire - Mon Feb 02, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it will be presenting preclinical data from two biodefense programs at the upcoming American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research Meeting on February 9-11, 2015 to be held at the Washington Marriott Wardman Park, 2660 Woodley Rd. NW.
XON: 41.17 (+1.09)
Soligenix Announces Publication Successfully Demonstrating Enhanced Immunogenicity of its Heat-Stable Anthrax Vaccine
PR Newswire - Thu Jan 29, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the publication of data demonstrating enhanced immunogenicity and rapid action of its anthrax vaccine, VeloThrax(TM). VeloThrax(TM) employs a derivative of recombinant protective antigen, termed Dominant Negative Inhibitor (DNI), which is a candidate for inclusion in a next generation anthrax vaccine. The use of the Company's proprietary vaccine stabilization technology, ThermoVax(TM), has been previously demonstrated to enhance the thermostability of VeloThrax(TM), enabling distribution without cold chain requirements. In this work, the use of two adjuvants, aluminum hydroxide and Glycopyranoside Lipid A (GLA) in conjunction with ThermoVax(TM), was demonstrated to further enhance the immunogenicity and rapid action of the vaccine. The results were published online in the Journal of Pharmaceutical Sciences and are available at the following link: http://onlinelibrary.wiley.com/doi/10.1002/jp...26F.f01t03 .
XON: 41.17 (+1.09)
FDA Grants Soligenix "Fast Track" Designation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma
PR Newswire - Wed Jan 07, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) has received "Fast Track" designation from the US Food and Drug Administration (FDA).
XON: 41.17 (+1.09)
Soligenix Announces Positive Preliminary Nonclinical Results in Macrophage Activation Syndrome
PR Newswire - Mon Jan 05, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that preliminary efficacy in an animal model of Macrophage Activation Syndrome (MAS) has been demonstrated with its SGX94 innate defense regulator (IDR) technology, significantly mitigating the pancytopenia characteristic of MAS.
XON: 41.17 (+1.09)
Cellceutix Overvalued By 90-99%
Ben Sharvy - at Seeking Alpha - Fri Jan 02, 4:21PM CST
VNDA: 10.16 (+0.15), VTAE: 12.42 (-0.34), XNCR: 15.73 (+0.41)
Soligenix Announces First Quarter 2015 Highlights and Financial Results
PR Newswire - Thu May 14, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today recent highlights and financial results for the first quarter ended March 31, 2015.
XON: 41.17 (+1.09)
Soligenix inks development deal with Emergent BioSolutions for ricin vaccine
Seeking Alpha - at Seeking Alpha - Wed May 13, 9:54AM CDT
EBS: 30.91 (+0.19)
Vista Partners Publishes May 2015 Macroeconomic & Investment Newsletter
Marketwired - Wed May 13, 8:01AM CDT
Vista Partners ("Vista"
has published its FREE Macroeconomic & Investment Monthly Newsletter for the month of May. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary. VUZI: 5.80 (+0.22), QQQ: 110.06 (+0.48)
Soligenix Announces Development Agreement with Emergent BioSolutions
PR Newswire - Wed May 13, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax(TM) drug substance protein antigen. RiVax(TM) is a vaccine candidate being developed to protect against ricin exposure. Soligenix will transfer the manufacturing processes and analytics to Emergent to conduct process development work that could potentially lead to a future commercial manufacturing collaboration.
EBS: 30.91 (+0.19), XON: 41.17 (+1.09)
Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO
PR Newswire - Mon May 04, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it will be presenting preclinical data from three of its biodefense programs at the upcoming Chemical and Biological Defense Science and Technology Conference on May 12-14, 2015 to be held at the America's Center Convention Complex at 701 Convention Plaza, St. Louis MO 63101.
XON: 41.17 (+1.09)
Soligenix Announces FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX203 in Pediatric Crohn's Disease
PR Newswire - Tue Apr 14, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that agreement has been reached with the US Food and Drug Administration (FDA) on the design of a pivotal, Phase 3 clinical trial evaluating its product, SGX203 (oral beclomethasone 17,21-dipropionate or BDP), in the treatment of pediatric Crohn's disease. SGX203 has previously been granted both orphan drug and fast track designations from the FDA for the treatment of Crohn's Disease in the pediatric population.
XON: 41.17 (+1.09)
Soligenix Inc.'s CEO Christopher Schaber Interviewed by The Life Sciences Report
Marketwired - Thu Apr 09, 8:15AM CDT
Orphan diseases associated with inflammation present excellent development opportunities for small biopharmaceutical companies and their investors. Additionally, inflammatory conditions can result from treatment with cancer therapeutics. The crossover between inflammation and oncology, coupled with vaccine programs of high strategic value, have allowed Soligenix Inc. (OTCQB: SNGX) to build a significant pipeline with substantial revenue potential. In this interview with The Life Sciences Report, Dr. Christopher J. Schaber, company President and CEO, outlines development programs targeting pediatric Crohn's disease, GI acute radiation syndrome, a rare lymphoma and the threat of ricin.
Vista Partners Publishes April 2015 Macroeconomic & Investment Newsletter
Marketwired - Wed Apr 08, 7:01AM CDT
Vista Partners ("Vista"
has published its FREE Macroeconomic & Investment Monthly Newsletter for the month of April. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary. VUZI: 5.80 (+0.22), SYRX: 1.93 (+0.05)
Soligenix Announces Recent Accomplishments and Year-End 2014 Financial Results
PR Newswire - Tue Mar 24, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today recent accomplishments and financial results for the year ended December 31, 2014.
XON: 41.17 (+1.09)
Soligenix Announces Publication of Successful Preclinical Efficacy and Immunogenicity Results for Ricin Toxin Vaccine
PR Newswire - Wed Mar 11, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the publication of data demonstrating complete protection and immunogenicity of its ricin vaccine, RiVax(TM), in preclinical studies, with analyses of previous human clinical samples. RiVax(TM) employs a derivative of recombinant ricin toxin A chain. The use of the Company's proprietary vaccine stabilization technology, ThermoVax(TM) has been previously demonstrated to enhance thermostability of RiVax(TM), enabling distribution without cold chain requirements. In this work, vaccination with RiVax(TM) provided 100% protection for non-human primates (NHPs) subsequently exposed to lethal doses of aerosolized ricin. Evaluation of antibodies produced by the NHPs after vaccination identified specific neutralizing antibodies which were also expressed by humans previously vaccinated with RiVax(TM). The results were published online in the Proceedings of the National Academy of Sciences and are available at the following link: http://www.pnas.org/content/early/2015/03/05/...f32229914c .
XON: 41.17 (+1.09)
Soligenix Announces Positive Recommendation by Data Review Committee on its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
PR Newswire - Tue Mar 03, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has received a positive recommendation from the Data Review Committee (DRC) to continue enrolling into the company's Phase 2 study evaluating SGX942, a first-in-class innate defense regulator (IDR), as a treatment for oral mucositis in patients undergoing chemoradiation (CRT) therapy for head and neck cancer. Following DRC review of available data on the subjects enrolled in the trial, the committee recommended that enrollment include an additional 20 subjects randomized into either a single SGX942 dose group or the placebo group to allow for a more targeted assessment of the drug's potential effect and to inform final dose selection in this patient population.
XON: 41.17 (+1.09)
Soligenix's SGX943 And SGX101 May Be A Solution For Melioidosis Treatment
Grant Zeng, CFA - Seeking Alpha - Wed Feb 18, 1:08PM CST
A recent news release from the US Centers for Disease Control and Prevention (CDC) on inquiry into melioidosis illness at Tulane National Research Center (TNPRC) has raised the visibility and awareness of melioidosis among healthcare...
XON: 41.17 (+1.09)
Ricin Toxin Vaccine Poster Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PR Newswire - Fri Feb 13, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it presented data from its recent preclinical study that demonstrated the efficacy and safety of its heat-stabilized ricin toxin vaccine (RiVax(TM)) in a non-human primate (NHP) lethal aerosolized ricin exposure model. The data was presented in a poster session at the American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research meeting on Wednesday, February 11, 2015 at Washington Marriott Wardman Park, 2660 Woodley Rd. NW in Washington, DC.
XON: 41.17 (+1.09)
Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PR Newswire - Wed Feb 11, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it presented data from its recent preclinical study that demonstrated statistically significant efficacy of SGX943 in a mouse model of acute, lethal pneumonic melioidosis. The data was presented in an oral presentation at the American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research meeting on Tuesday, February 10, 2015 at Washington Marriott Wardman Park, 2660 Woodley Rd. NW in Washington, DC.
XON: 41.17 (+1.09)
Soligenix to Present at the 17th Annual BIO CEO & Investor Conference in New York City
PR Newswire - Thu Feb 05, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 17th Annual BIO CEO Investor Conference in New York City, on Tuesday, February 10, 2015 at 1:30 PM Eastern Standard Time (EST). The presentation will take place in the Conrad room at the Waldorf Astoria.
XON: 41.17 (+1.09)
Soligenix Announces Presentation and Poster at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PR Newswire - Mon Feb 02, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it will be presenting preclinical data from two biodefense programs at the upcoming American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research Meeting on February 9-11, 2015 to be held at the Washington Marriott Wardman Park, 2660 Woodley Rd. NW.
XON: 41.17 (+1.09)
Soligenix Announces Publication Successfully Demonstrating Enhanced Immunogenicity of its Heat-Stable Anthrax Vaccine
PR Newswire - Thu Jan 29, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the publication of data demonstrating enhanced immunogenicity and rapid action of its anthrax vaccine, VeloThrax(TM). VeloThrax(TM) employs a derivative of recombinant protective antigen, termed Dominant Negative Inhibitor (DNI), which is a candidate for inclusion in a next generation anthrax vaccine. The use of the Company's proprietary vaccine stabilization technology, ThermoVax(TM), has been previously demonstrated to enhance the thermostability of VeloThrax(TM), enabling distribution without cold chain requirements. In this work, the use of two adjuvants, aluminum hydroxide and Glycopyranoside Lipid A (GLA) in conjunction with ThermoVax(TM), was demonstrated to further enhance the immunogenicity and rapid action of the vaccine. The results were published online in the Journal of Pharmaceutical Sciences and are available at the following link: http://onlinelibrary.wiley.com/doi/10.1002/jp...26F.f01t03 .
XON: 41.17 (+1.09)
FDA Grants Soligenix "Fast Track" Designation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma
PR Newswire - Wed Jan 07, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) has received "Fast Track" designation from the US Food and Drug Administration (FDA).
XON: 41.17 (+1.09)
Soligenix Announces Positive Preliminary Nonclinical Results in Macrophage Activation Syndrome
PR Newswire - Mon Jan 05, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that preliminary efficacy in an animal model of Macrophage Activation Syndrome (MAS) has been demonstrated with its SGX94 innate defense regulator (IDR) technology, significantly mitigating the pancytopenia characteristic of MAS.
XON: 41.17 (+1.09)
Cellceutix Overvalued By 90-99%
Ben Sharvy - at Seeking Alpha - Fri Jan 02, 4:21PM CST
VNDA: 10.16 (+0.15), VTAE: 12.42 (-0.34), XNCR: 15.73 (+0.41)
